Hammadi Ayadi, CEO of Sidi Thabet BiotechPole, proudly introduces the launch of the site’s incubator and announces the soon-to-come opening of the company cluster. This will provide a platform for the fusion of theoretical research and technical knowhow and aid the development of the first biotech drug made in Tunisia by 2020. The future of biotechnological research looks bright under the umbrella of an ambitious, passionate but nonetheless down-to-earth BiotechPole.
Ayadi, what is BiotechPole Sidi Thabet and what exactly are its main missions?
"In 2020, the BiotechPole will have successfully opened its Technology Research Center (CRT) that will encompass an operational production line and employees that are perfectly able to operate it."
